Floatz logo

TENOXICAM

Migraine

Haydarpasa Numune Training and Research HospitalSmall moleculePhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
73/ 100

Competitive context

106 Active assets in the Migraine cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
mk-1602
H. Lundbeck A/S
Phase 4BBB

View all 50 →

Same molecule, other indications

TENOXICAM is also rated in:

Analgesic AffectDormant
BB
Indicative ·
65 / 100
View asset →
Emergency MedicineDormant
BB
Indicative ·
65 / 100
View asset →
Pain, PostoperativeDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →